Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss
| العنوان: | Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss |
|---|---|
| المؤلفون: | Natalie Durell, Rachel Franks, Scott Coon, Kevin Cowart, Nicholas W. Carris |
| المصدر: | Journal of Pharmacy Technology. 38:283-288 |
| بيانات النشر: | SAGE Publications, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Pharmaceutical Science |
| الوصف: | Background: Depression and obesity have a bidirectional relationship making the management of one, without the other, problematic. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a preferred medication class for diabetes and obesity treatment given their weight loss effect; however, it is not known how antidepressants impact this effect. Objective: To assess the impact of antidepressant use on GLP-1 RA-associated weight loss in patients with or without type 2 diabetes mellitus. Methods: This was a retrospective, propensity matched, cohort study conducted using TriNetX. The study identified patients initiating a GLP-1 RA being treated with citalopram/escitalopram, bupropion, or no antidepressant. Cohorts were propensity score matched to analyze the primary outcome of mean end-of-study (77-371 days) body weight. Results: An initial query identified 31 273 patients eligible for analysis (30 160 receiving no antidepressant, 311 receiving bupropion, and 802 receiving citalopram/escitalopram). After propensity score matching, the study found patients receiving citalopram/escitalopram were taking more antidiabetic therapies at baseline compared with patients not treated with an antidepressant. Patients in the antidepressant cohorts experienced less weight loss compared with their respective matched cohorts not receiving antidepressants (citalopram/escitalopram −0.73 kg versus −1.74 kg; bupropion −0.84 kg versus −3.46 kg). Only the bupropion cohort was significantly heavier at end-of-study versus the non-antidepressant cohort (108 kg versus 103 kg, P = 0.018). Conclusion and Relevance: Antidepressants may diminish the weight loss effect of GLP-1 RAs. Additional research is needed to assess whether all GLP-1 RAs are affected similarly and the optimal weight loss strategies in patients receiving antidiabetic therapy with comorbid depression. |
| تدمد: | 1549-4810 8755-1225 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::385ffe599d11bbc5f13ca1e1bd307a3b https://doi.org/10.1177/87551225221110850 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....385ffe599d11bbc5f13ca1e1bd307a3b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15494810 87551225 |
|---|